Clinical Pharmacokinetics

, Volume 45, Issue 9, pp 931–956 | Cite as

Prediction of the Clearance of Eleven Drugs and Associated Variability in Neonates, Infants and Children

  • Trevor N. Johnson
  • Amin Rostami-Hodjegan
  • Geoffrey T. Tucker
Original Research Article

Abstract

Background

Prediction of the exposure of neonates, infants and children to xenobiotics is likely to be more successful using physiologically based pharmacokinetic models than simplistic allometric scaling, particularly in younger children. However, such models require comprehensive information on the ontogeny of anatomical, physiological and biochemical variables; data that are not available from single sources.

The Simcyp® software integrates demographic, genetic, physiological and pathological information on adults with in vitro data on human drug metabolism and transport to predict population distributions of drug clearance (CL) and the extent of metabolic drug-drug interactions. The algorithms have now been extended to predict clearance and its variability in paediatric populations by incorporating information on developmental physiology and the ontogeny of specific cytochrome P450s.

Methods

Values of the clearance (median and variability) of 11 drugs (midazolam [oral and intravenous], caffeine, carbamazepine, cisapride, theophylline, diclofenac, omeprazole, S-warfarin, phenytoin, gentamicin and vancomycin) were predicted for 2000 virtual subjects (birth to 18 years). In vitro enzyme pharmacokinetic parameters (maximum rate of metabolism [Vmax] and Michaelis-Menten constant [Km]) and in vivo clearance data were obtained from the literature.

Results

In neonates 70% (7/10) of predicted median clearance values were within 2-fold of the observed values. Corresponding results for infants, children and adolescents were 100% (9/9), 89% (17/19) and 94% (17/18), respectively. Predicted variability (95% confidence interval) was within 2-fold of the observed values in 70% (7/10), 67% (6/9), 63% (12/19) and 55% (10/18) of cases, respectively. The accuracy of the physiologically based model incorporated in the Simcyp® software was superior to that of simple allometry, especially in children <2 years old.

Conclusion

The in silico prediction of pharmacokinetic behaviour in paediatric patients is not intended to replace clinical studies. However, it provides a valuable aid to decision-making with regard to first-time dosing in children and study design. The clinical study then becomes ‘confirmatory’ rather than ‘exploratory’.

References

  1. 1.
    de Zwart LL, Haenen HE, Versantvoort CH, et al. Role of biokinetics in risk assessment of drags and chemicals in children. Regul Toxicol Pharmacol 2004 Jun; 9(3): 282–309Google Scholar
  2. 2.
    Mahmood I. Prediction of drug clearance in children from adults: a comparison of several allometric methods. Br J Clin Pharmacol 2006; 61(5): 545–87PubMedGoogle Scholar
  3. 3.
    Pelekis M, Gephart LA, Lerman SE. Physiological-model-based derivation of the adult and child pharmacokinetic intraspecies uncertainty factors for volatile organic compounds. Regul Toxicol Pharmacol 2001 Feb; 33(1): 12–20PubMedGoogle Scholar
  4. 4.
    Price K, Haddad S, Krishnan K. Physiological modeling of age-specific changes in the pharmacokinetics of organic chemicals in children. J Toxicol Environ Health A 2003 Mar; 66(5): 417–33PubMedGoogle Scholar
  5. 5.
    Gentry PR, Covington TR, Clewell III HJ. Evaluation of the potential impact of pharmacokinetic differences on tissue dosimetry in offspring during pregnancy and lactation. Regul Toxicol Pharmacol 2003 Aug; 38(1): 1–16PubMedGoogle Scholar
  6. 6.
    Bjorkman S. Prediction of drag disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. Br J Clin Pharmacol 2005 Jun; 59(6): 691–704PubMedGoogle Scholar
  7. 7.
    Ginsberg G, Hattis D, Russ A, et al. Physiologically based pharmacokinetic (PBPK) modeling of caffeine and theophylline in neonates and adults: implications for assessing children’s risks from environmental agents. J Toxicol Environ Health A 2004 Feb; 67(4): 297–329PubMedGoogle Scholar
  8. 8.
    Proctor NJ, Smith CY, Rostami-Hodjegan A, et al. Population clearance prediction of 13 drugs using Simcyp. Pharmacologist 2002; 44 Suppl. 1: LB87Google Scholar
  9. 9.
    Rostami-Hodjegan A, Tucker GT. “In silico” simulations to assess the “in vivo” consequences of “in vitro” metabolic drag-drug interactions. Drag Discov Today 2004; 1(4): 441–8Google Scholar
  10. 10.
    Yang J, Rostami-Hodjegan A, Tucker GT. Prediction of fluconazole interaction with midazolam and triazolam: incorporating population variability [abstract]. Br J Clin Pharmacol 2001; 52: 472PGoogle Scholar
  11. 11.
    Yang J, Rostami-Hodjegan A, Tucker GT. Prediction of ritonavir interaction with sildenafil (Viagra) incorporating population variability [abstract]. Br J Clin Pharmacol 2002; 53: 438PGoogle Scholar
  12. 12.
    Cole TJ, Freeman JV, Preece MA. British 1990 growth reference centiles for weight, height, body mass index and head circumference fitted by maximum penalized likelihood. Stat Med 1998 Mar; 17(4): 407–29PubMedGoogle Scholar
  13. 13.
    DuBois D, DuBois EF. A formula to estimate the approximate surface area if height and weight are known. Arch Intern Med 1916; 17: 863–71Google Scholar
  14. 14.
    Haycock GB, Schwartz GJ, Wisotsky DH. Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults. J Pediatr 1978 Jul; 93(1): 62–6PubMedGoogle Scholar
  15. 15.
    Brion L, Fleischman AR, Schwartz GJ. Evaluation of four length-weight formulas for estimating body surface area in newborn infants. J Pediatr 1985 Dec; 107(5): 801–3PubMedGoogle Scholar
  16. 16.
    Cole TJ, Freeman JV, Preece MA. Body mass index reference curves for the UK, 1990. Arch Dis Child 1995 Aug; 73(1): 25–9PubMedGoogle Scholar
  17. 17.
    Livingston EH, Lee S. Body surface area prediction in normal-weight and obese patients. Am J Physiol Endocrinol Metab 2001 Oct; 281(3): E586–91PubMedGoogle Scholar
  18. 18.
    Johnson TN, Tucker GT, Tanner MS, et al. Changes in liver volume from birth to adulthood: a meta analysis. Liver Transpl 2005; 12: 1481–93Google Scholar
  19. 19.
    Gabrielsson J, Weiner D. Pharmacokinetic and pharmacodynamic data analysis. 3rd ed. Stockholme: Swedish Pharmaceutical Press, 2000Google Scholar
  20. 20.
    Basic anatomical and physiological data for use in radiological protection: reference values. A report of age- and genderrelated differences in the anatomical and physiological characteristics of reference individuals. ICRP Publication 89. Ann ICRP 2002; 32(3-4): 5–265Google Scholar
  21. 21.
    Guyton AC, Hall JE. Cardiac output, venous return, and their regulation. In: Guyton AC, Hall JE, editors. Textbook of medical physiology. 9th ed. Philadelphia (PA): WB Saunders, 1996: 1148Google Scholar
  22. 22.
    de Simone G, Devereux RB, Daniels SR, et al. Stroke volume and cardiac output in normotensive children and adults: assessment of relations with body size and impact of overweight. Circulation 1997 Apr; 95(7): 1837–43PubMedGoogle Scholar
  23. 23.
    Schwartz GJ, Haycock GB, Edelmann CM, et al. A simple estimate of glomerular filtration in children derived from body length and plasma creatinine. Pediatr 1976; 58: 259–63Google Scholar
  24. 24.
    Rowland M, Tozer TN. Clinical pharmacokinetics concepts and applications. 3rd ed. Philadelphia (PA): Lippincott Williams and Wilkins, 1995Google Scholar
  25. 25.
    Schull BC, Haughey D, Koup JR, A useful method for predicting creatinine clearance in children. Clin Chem 1978; 24: 1167–1169Google Scholar
  26. 26.
    Rubin MI, Bruck E, Rapoport M, et al. Maturation of renal function in childhood: clearance studies. J Clin Invest 1949; 28: 1144–62Google Scholar
  27. 27.
    Fasouliotis SJ, Achiron R, Kivilevitch Z, et al. The human fetal venous system: normal embryologic, anatomic, and physiologic characteristics and developmental abnormalities. J Ultrasound Med 2002 Oct; 21(10): 1145–58PubMedGoogle Scholar
  28. 28.
    Tateishi T, Nakura H, Asoh M, et al. A comparison of hepatic cytochrome P450 protein expression between infancy and postinfancy. Life Sci 1997; 61(26): 2567–74PubMedGoogle Scholar
  29. 29.
    Sonnier M, Cresteil T. Delayed ontogenesis of CYP1A2 in the human liver. Eur J Biochem 1998 Feb; 251(3): 893–8PubMedGoogle Scholar
  30. 30.
    de Wildt SN, Johnson TN, Choonara I. The effects of age on drug metabolism. Paediatric and Perinatal Drug Therapy 2003; 5: 101–6Google Scholar
  31. 31.
    Treluyer JM, Gueret G, Cheron G, et al. Developmental expression of CYP2C and CYP2C-dependent activities in the human liver: in-vivo/in-vitro correlation and inducibility. Pharmacogenetics 1997 Dec; 7(6): 441–52PubMedGoogle Scholar
  32. 32.
    Koukouritaki SB, Manro JR, Marsh SA, et al. Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther 2004 Mar; 308(3): 965–74PubMedGoogle Scholar
  33. 33.
    Treluyer JM, Jacqz-Aigrain E, Alvarez F, et al. Expression of CYP2D6 in developing human liver. Eur J Biochem 1991 Dec 5; 202(2): 583–8PubMedGoogle Scholar
  34. 34.
    Vieira I, Sonnier M, Cresteil T. Developmental expression of CYP2E1 in the human liver. Hypermethylation control of gene expression during the neonatal period. Eur J Biochem 1996 Jun; 238(2): 476–83PubMedGoogle Scholar
  35. 35.
    Johnsrud EK, Koukouritaki SB, Divakaran K, et al. Human hepatic CYP2E1 expression during development. J Pharmacol Exp Ther 2003 Oct; 307(1): 402–7PubMedGoogle Scholar
  36. 36.
    Lacroix D, Sonnier M, Moncion A, et al. Expression of CYP3A in the human liver: evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem 1997 Jul; 247(2): 625–34PubMedGoogle Scholar
  37. 37.
    Treluyer JM, Bowers G, Cazali N, et al. Oxidative metabolism of amprenavir in the human liver: effect of the CYP3A maturation. Drug Metab Dispos 2003 Mar; 31(3): 275–81PubMedGoogle Scholar
  38. 38.
    Stevens JC, Hines RN, Gu C, et al. Developmental expression of the major human hepatic CYP3A enzymes. J Pharmacol Exp Ther 2003 Nov; 307(2): 573–82PubMedGoogle Scholar
  39. 39.
    Johnson TN, Tanner MS, Taylor CJ, et al. Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosis. Br J Clin Pharmacol 2001 May; 51(5): 451–60PubMedGoogle Scholar
  40. 40.
    Akaike H. Information theory as an extension of the maximum likelihood principle. In: Petrov BN, Csaki F, editors. Second International Symposium on information theory. Budapest: Akademiai Kiado, 1973: 267–81Google Scholar
  41. 41.
    Alcorn J, McNamara PJ. Ontogeny of hepatic and renal systematic clearance pathways in infants part II. Clin Pharmacokinet 2002; 41(13): 1077–94PubMedGoogle Scholar
  42. 42.
    Rowland-Yeo K, Rostami-Hodjegan A, Tucker GT. Abundance of cytochrome P450 in human liver:a meta analysis. Br J Clin Pharmacol 2003; 57(5): 687–8Google Scholar
  43. 43.
    Gow PJ, Ghabrial H, Smallwood RA, et al. Neonatal hepatic drug elimination. Pharmacol Toxicol 2001 Jan; 88(1): 3–15PubMedGoogle Scholar
  44. 44.
    Wilson ZE, Rostami-Hodjegan A, Burn JL, et al. Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver. Br J Clin Pharmacol 2003 Oct; 56(4): 433–40PubMedGoogle Scholar
  45. 45.
    Pelkonen O, Kaltiala EH, Larmi TK, et al. Comparison of activities of drug-metabolizing enzymes in human fetal and adult livers. Clin Pharmacol Ther 1973 Sep-Oct; 14(5): 840–6PubMedGoogle Scholar
  46. 46.
    Peters AM, Gordon I, Sixt R. Normalization of glomerular filtration rate in children: body surface area, body weight or extracellular fluid volume? J Nucl Med 1994 Mar; 35(3): 438–44PubMedGoogle Scholar
  47. 47.
    West JR, Smith HW, Chasis H. Glomerular filtration rate effective renal blood flow and maximal tubular excretory capacity in infancy. J Pediatr 1948; 32: 10–8PubMedGoogle Scholar
  48. 48.
    Guignard JP, Torrado A, Da Cunha O, et al. Glomerular filtration rate in the first three weeks of life. J Pediatr 1975 Aug; 87(2): 268–72PubMedGoogle Scholar
  49. 49.
    Fawer CL, Torrado A, Guignard JP. Maturation of renal function in full-term and premature neonates. Helv Paediatr Acta 1979 Feb; 34(1): 11–21PubMedGoogle Scholar
  50. 50.
    Coulthard MG. Comparison of methods of measuring renal function in preterm babies using inulin. J Pediatr 1983 Jun; 102(6): 923–30PubMedGoogle Scholar
  51. 51.
    Strauss J, Daniel SS, James LS. Postnatal adjustment in renal function. Pediatrics 1981 Dec; 68(6): 802–8PubMedGoogle Scholar
  52. 52.
    Heilbron DC, Holliday MA, al-Dahwi A, et al. Expressing glomerular filtration rate in children. Pediatr Nephrol 1991 Jan; 5(1): 5–11PubMedGoogle Scholar
  53. 53.
    Stewart CF, Hampton EM. Effect of maturation on drug disposition in pediatric patients. Clin Pharm 1987 Jul; 6(7): 548–64PubMedGoogle Scholar
  54. 54.
    Traub SL, Johnson CE. Comparison of methods of estimating creatinine clearance in children. Am J Hosp Pharm 1980; 37: 195–201PubMedGoogle Scholar
  55. 55.
    McNamara PJ, Alcorn J. Protein binding predictions in infants. AAPS PharmSci 2002; 4(1): E4Google Scholar
  56. 56.
    Wallace S. Factors affecting drug-protein binding in the plasma of newborn infants. Br J Clin Pharmacol 1976 Jun; 3(3): 510–2PubMedGoogle Scholar
  57. 57.
    Kuhnz W, Nau H. Differences in in vitro binding of diazepam and N-desmethyldiazepam to maternal and fetal plasma proteins at birth: relation to free fatty acid concentration and other parameters. Clin Pharmacol Ther 1983 Aug; 34(2): 220–6PubMedGoogle Scholar
  58. 58.
    Nau H, Luck W, Kuhnz W, et al. Serum protein binding of diazepam, desmethyldiazepam, furosemide, indomethacin, warfarin, and phenobarbital in human fetus, mother, and new-born infant. Pediatr Pharmacol (New York) 1983; 3(3–4): 219–27Google Scholar
  59. 59.
    Veering BT, Burm AG, Souverijn JH, et al. The effect of age on serum concentrations of albumin and alpha 1-acid glycoprotein. Br J Clin Pharmacol 1990 Feb; 29(2): 201–6PubMedGoogle Scholar
  60. 60.
    ICRP. International commission on radiological protection. Report of the task group on reference man: anatomical, physiological and metabolic characteristics. Oxford, New York, Tokyo: Pergamon Press, 1975Google Scholar
  61. 61.
    Valetin J. Basic anatomical and physiological data for use in radiological protection: reference values. A report of age- and gender related differences in the anatomical and physiological characteristics of reference individuals. ICRP Publication 89. Ann ICRP 2002; 32(3–4): 5–265Google Scholar
  62. 62.
    Yang J, Tucker GT, Rostami-Hodjegan A. Cytochrome P450 3A expression and activity in the human small intestine. Clin Pharmacol Ther 2004 Oct; 76(4): 391PubMedGoogle Scholar
  63. 63.
    Paine MF, Shen DD, Kunze KL, et al. First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 1996 Jul; 60(1): 14–24PubMedGoogle Scholar
  64. 64.
    Alionen H, Ziegler G, Klotz U. Midazolam kinetics. Clin Pharmacol Ther 1981 Nov; 30(5): 653–61Google Scholar
  65. 65.
    Perloff MD, von Moltke LL, Court MH, et al. Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms. J Pharmacol Exp Ther 2000 Feb; 292(2): 618–28PubMedGoogle Scholar
  66. 66.
    Gorski JC, Hall SD, Jones DR, et al. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 1994 Apr 29; 47(9): 1643–53PubMedGoogle Scholar
  67. 67.
    Obach RS. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 1999 Nov; 27(11): 1350–9PubMedGoogle Scholar
  68. 68.
    McLure JA, Miners JO, Birkett DJ. Nonspecific binding of drugs to human liver microsomes. Br J Clin Pharmacol 2000 May; 49(5): 453–61PubMedGoogle Scholar
  69. 69.
    Birkett DJ, Miners JO. Caffeine renal clearance and urine caffeine concentrations during steady state dosing. Implications for monitoring caffeine intake during sports events. Br J Clin Pharmacol 1991 Apr; 31(4): 405–8PubMedGoogle Scholar
  70. 70.
    Lelo A, Birkett DJ, Robson RA, et al. Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. Br J Clin Pharmacol 1986 Aug; 22(2): 177–82PubMedGoogle Scholar
  71. 71.
    Ha HR, Chen J, Krahenbuhl S, et al. Biotransformation of caffeine by cDNA-expressed human cytochromes P-450. Eur J Clin Pharmacol 1996; 49(4): 309–15PubMedGoogle Scholar
  72. 72.
    Bort R, Mace K, Boobis A, et al. Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol 1999 Sep; 58(5): 787–96PubMedGoogle Scholar
  73. 73.
    Kerr BM, Thummel KE, Wurden CJ, et al. Human liver carbamazepine metabolism: role of CYP3A4 and CYP2C8 in 10, 11-epoxide formation. Biochem Pharmacol 1994 Jun; 47(11): 1969–79PubMedGoogle Scholar
  74. 74.
    Pearce RE, Gotschall RR, Kearns GL, et al. Cytochrome P450 Involvement in the biotransformation of cisapride and racemic norcisapride in vitro: differential activity of individual human CYP3A isoforms. Drug Metab Dispos 2001 Dec; 29(12): 1548–54PubMedGoogle Scholar
  75. 75.
    Desta Z, Soukhova N, Mahal SK, et al. Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies. Drug Metab Dispos 2000 Jul; 28(7): 789–800PubMedGoogle Scholar
  76. 76.
    Desta Z, Soukhova N, Morocho AM, et al. Stereoselective metabolism of cisapride and enantiomer-enantiomer interaction in human cytochrome P450 enzymes: major role of CYP3A. J Pharmacol Exp Ther 2001 Aug; 298(2): 508–20PubMedGoogle Scholar
  77. 77.
    Abernethy DR, Kaminsky LS, Dickinson TH. Selective inhibition of warfarin metabolism by diltiazem in humans. J Pharmacol Exp Ther 1991 Apr; 257(1): 411–5PubMedGoogle Scholar
  78. 78.
    Takahashi H, Kashima T, Nomoto S, et al. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. Pharmacogenetics 1998 Oct; 8(5): 365–73PubMedGoogle Scholar
  79. 79.
    Takanashi K, Tainaka H, Kobayashi K, et al. CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics 2000 Mar; 10(2): 95–104PubMedGoogle Scholar
  80. 80.
    Yamazaki H, Inoue K, Shaw PM, et al. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. J Pharmacol Exp Ther 1997 Nov; 283(2): 434–42PubMedGoogle Scholar
  81. 81.
    Karam WG, Goldstein JA, Lasker JM, et al. Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metab Dispos 1996 Oct; 24(10): 1081–7PubMedGoogle Scholar
  82. 82.
    Regardh CG, Andersson T, Lagerstrom PO, et al. The pharmacokinetics of omeprazole in humans: a study of single intravenous and oral doses. Ther Drug Monit 1990 Mar; 12(2): 163–72PubMedGoogle Scholar
  83. 83.
    Ha HR, Chen J, Freiburghaus AU, et al. Metabolism of theophylline by cDNA-expressed human cytochromes P-450. Br J Clin Pharmacol 1995 Apr; 39(3): 321–6PubMedGoogle Scholar
  84. 84.
    Bajpai M, Roskos LK, Shen DD, et al. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab Dispos 1996 Dec; 24(12): 1401–3PubMedGoogle Scholar
  85. 85.
    Matzke GR, Millikin SP, Kovarik JM. Variability in pharmacokinetic values for gentamicin, tobramycin, and netilmicin in patients with renal insufficiency. Clin Pharm 1989 Nov; 8(11): 800–6PubMedGoogle Scholar
  86. 86.
    Wallace AW, Jones M, Bertino Jr JS. Evaluation of four once-daily aminoglycoside dosing nomograms. Pharmacotherapy 2002 Sep; 22(9): 1077–83PubMedGoogle Scholar
  87. 87.
    Pou L, Roseli M, Lopez R, et al. Changes in vancomycin pharmacokinetics during treatment. Ther Drug Monit 1996 Apr; 18(2): 149–53PubMedGoogle Scholar
  88. 88.
    Rodvold KA, Everett JA, Pryka RD, et al. Pharmacokinetics and administration regimens of vancomycin in neonates, infants and children. Clin Pharmacokinet 1997 Jul; 33(1): 32–51PubMedGoogle Scholar
  89. 89.
    Rostami-Hodjegan A, Tucker GT. The effects of portal shunts on intestinal cytochrome P450 3A activity. Hepatology 2002 Jun; 35(6): 1549–50PubMedGoogle Scholar
  90. 90.
    Yang JS, Rostami-Hodjegan A, Tucker GT. Prediction of ketoconazole interaction with midazolam, alprazolam and triazolam: incorporating population variability. Br J Clin Pharmacol 2001; 52: 472PGoogle Scholar
  91. 91.
    Dahl ML, Johansson I, Bertilsson L, et al. Ultrarapid hydroxylation of debrisoquine in a Swedish population: analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995 Jul; 274(1): 516–20PubMedGoogle Scholar
  92. 92.
    Inoue S, Howgate EM, Rowland Yeo K, et al. Production of in vivo drug clearance from in vitro data. II: potentail inter-ethnic differences. Xenobiotica 2006; 36(3): 499–53PubMedGoogle Scholar
  93. 93.
    de Wildt SN, de Hoog M, Vinks AA, et al. Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients. Crit Care Med 2003 Jul; 31(7): 1952–8PubMedGoogle Scholar
  94. 94.
    Payne K, Mattheyse FJ, Liebenberg D, et al. The pharmacokinetics of midazolam in paediatric patients. Eur J Clin Pharmacol 1989; 37(3): 267–72PubMedGoogle Scholar
  95. 95.
    Reed MD, Rodarte A, Blumer JL, et al. The single-dose pharmacokinetics of midazolam and its primary metabolite in pediatric patients after oral and intravenous administration. J Clin Pharmacol 2001 Dec; 41(12): 1359–69PubMedGoogle Scholar
  96. 96.
    Clausen TG, Wolff J, Hansen PB, et al. Pharmacokinetics of midazolam and alpha-hydroxy-midazolam following rectal and intravenous administration. Br J Clin Pharmacol 1988 Apr; 25(4): 457–63PubMedGoogle Scholar
  97. 97.
    Hamaoka N, Oda Y, Hase I, et al. Propofol decreases the clearance of midazolam by inhibiting CYP3A4: an in vivo and in vitro study. Clin Pharmacol Ther 1999 Aug; 66(2): 110–7PubMedGoogle Scholar
  98. 98.
    Palkama VJ, Ahonen J, Neuvonen PJ, et al. Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam. Clin Pharmacol Ther 1999 Jul; 66(1): 33–9PubMedGoogle Scholar
  99. 99.
    Platten HP, Schweizer E, Dilger K, et al. Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. Clin Pharmacol Ther 1998 May; 63(5): 552–60PubMedGoogle Scholar
  100. 100.
    Eeckhoudt SL, Desager JP, Horsmans Y, et al. Sensitive assay for midazolam and its metabolite 1′-hydroxymidazolam in human plasma by capillary high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1998 Jun; 710(1–2): 165–71PubMedGoogle Scholar
  101. 101.
    Dingemanse J, van Gerven JM, Schoemaker RC, et al. Integrated pharmacokinetics and pharmacodynamics of Ro 48-6791, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects. Br J Clin Pharmacol 1997 Nov; 44(5): 477–86PubMedGoogle Scholar
  102. 102.
    Mould DR, DeFeo TM, Reele S, et al. Simultaneous modeling of the pharmacokinetics and pharmacodynamics of midazolam and diazepam. Clin Pharmacol Ther 1995 Jul; 58(1): 35–43PubMedGoogle Scholar
  103. 103.
    Mandema JW, Tuk B, van Steveninck AL, et al. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers. Clin Pharmacol Ther 1992 Jun; 51(6): 715–28PubMedGoogle Scholar
  104. 104.
    Lin YS, Lockwood GF, Graham MA, et al. In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. Pharmacogenetics 2001 Dec; 11(9): 781–91PubMedGoogle Scholar
  105. 105.
    Wang Z, Gorski JC, Hamman MA, et al. The effects of St John’s wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 2001 Oct; 70(4): 317–26PubMedGoogle Scholar
  106. 106.
    Gorski JC, Jones DR, Haehner-Daniels BD, et al. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 1998 Aug; 64(2): 133–43PubMedGoogle Scholar
  107. 107.
    de Wildt SN, Kearns GL, Hop WC, et al. Pharmacokinetics and metabolism of oral midazolam in preterm infants. Br J Clin Pharmacol 2002 Apr; 53(4): 390–2PubMedGoogle Scholar
  108. 108.
    Carrillo JA, Ramos SI, Agundez JA, et al. Analysis of midazolam and metabolites in plasma by high-performance liquid chromatography: probe of CYP3A. Ther Drug Monit 1998 Jun; 20(3): 319–24PubMedGoogle Scholar
  109. 109.
    Kinirons MT, O’shea D, Kim RB, et al. Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A. Clin Pharmacol Ther 1999 Sep; 66(3): 224–31PubMedGoogle Scholar
  110. 110.
    Pons G, Carrier O, Richard MO, et al. Developmental changes of caffeine elimination in infancy. Dev Pharmacol Ther 1988; 11(5): 258–64PubMedGoogle Scholar
  111. 111.
    Akinyinka OO, Sowunmi A, Honeywell R, et al. The pharmacokinetics of caffeine in Nigerian children suffering from malaria and kwashiorkor. Eur J Clin Pharmacol 2000 May; 56(2): 153–8PubMedGoogle Scholar
  112. 112.
    Carrillo JA, Christensen M, Ramos SI, et al. Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine. Ther Drug Monit 2000 Aug; 22(4): 409–17PubMedGoogle Scholar
  113. 113.
    Hartter S, Ursing C, Morita S, et al. Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: a pilot study. Clin Pharmacol Ther 2001 Jul; 70(1): 10–6PubMedGoogle Scholar
  114. 114.
    Aranda JV, Collinge JM, Zinman R, et al. Maturation of caffeine elimination in infancy. Arch Dis Child 1979 Dec; 54(12): 946–9PubMedGoogle Scholar
  115. 115.
    Kinzig-Schippers M, Fuhr U, Zaigler M, et al. Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2. Clin Pharmacol Ther 1999 Mar; 65(3): 262–74PubMedGoogle Scholar
  116. 116.
    Wietholtz H, Zysset T, Marschall HU, et al. The influence of rifampin treatment on caffeine clearance in healthy man. J Hepatol 1995 Jan; 22(1): 78–81PubMedGoogle Scholar
  117. 117.
    Korpela R, Olkkola KT. Pharmacokinetics of intravenous diclofenac sodium in children. Eur J Clin Pharmacol 1990; 38(3): 293–5PubMedGoogle Scholar
  118. 118.
    Romsing J, Ostergaard D, Senderovitz T, et al. Pharmacokinetics of oral diclofenac and acetaminophen in children after surgery. Paediatr Anaesth 2001 Mar; 11(2): 205–13PubMedGoogle Scholar
  119. 119.
    Kirchheiner J, Meineke I, Steinbach N, et al. Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. Br J Clin Pharmacol 2003 Jan; 55(1): 51–61PubMedGoogle Scholar
  120. 120.
    Willis JV, Kendall MJ, Flinn RM, et al. The pharmacokinetics of diclofenac sodium following intravenous and oral administration. Eur J Clin Pharmacol 1979; 16(6): 405–10PubMedGoogle Scholar
  121. 121.
    Andersson T, Hassall E, Lundborg P, et al. Pharmacokinetics of orally administered omeprazole in children. International Pediatric Omeprazole Pharmacokinetic Group. Am J Gastroenterol 2000 Nov; 95(11): 3101–6PubMedGoogle Scholar
  122. 122.
    Kearns GL, Andersson T, James LP, et al. Omeprazole disposition in children following single-dose administration. J Clin Pharmacol 2003 Aug; 43(8): 840–8PubMedGoogle Scholar
  123. 123.
    Andersson T, Andren K, Cederberg C, et al. Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects. Br J Clin Pharmacol 1990 May; 29(5): 557–63PubMedGoogle Scholar
  124. 124.
    Preechagoon Y, Charles B, Piotrovskij V, et al. Population pharmacokinetics of enterally administered cisapride in young infants with gastro-oesophageal reflux disease. Br J Clin Pharmacol 1999 Nov; 48(5): 688–93PubMedGoogle Scholar
  125. 125.
    Desta Z, Rivisto KT, Lilja JJ, et al. Stereoselective pharmacokinetics of cisapride in healthy volunteers and the effect of repeated administration of grapefruit juice. Br J Clin Pharmacol 2001 Oct; 52(4): 399–407PubMedGoogle Scholar
  126. 126.
    Zhou H, Herron J, Clyde C, et al. Pharmacokinetic profile of cisapride 20mg after once- and twice-daily dosing. Clin Ther 1998 Mar-Apr; 20(2): 292–8PubMedGoogle Scholar
  127. 127.
    Summers B, Summers RS. Carbamazepine clearance in paediatric epilepsy patients: influence of body mass, dose, sex and co-medication. Clin Pharmacokinet 1989 Sep; 17(3): 208–16PubMedGoogle Scholar
  128. 128.
    Burstein AH, Horton RL, Dunn T, et al. Lack of effect of St John’s Wort on carbamazepine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 2000 Dec; 68(6): 605–12PubMedGoogle Scholar
  129. 129.
    Caraco Y, Zylber-Katz E, Berry EM, et al. Carbamazepine pharmacokinetics in obese and lean subjects. Ann Pharmacother 1995 Sep; 29(9): 843–7PubMedGoogle Scholar
  130. 130.
    Sanchez-Alcaraz A, Quintana MB, Lopez E, et al. Effect of vigabatrin on the pharmacokinetics of carbamazepine. J Clin Pharm Ther 2002 Dec; 27(6): 427–30PubMedGoogle Scholar
  131. 131.
    Kraus DM, Fischer JH, Reitz SJ, et al. Alterations in theophylline metabolism during the first year of life. Clin Pharmacol Ther 1993 Nov; 54(4): 351–9PubMedGoogle Scholar
  132. 132.
    Loughnan PM, Sitar DS, Ogilvie RI, et al. Pharmacokinetic analysis of the disposition of intravenous theophylline in young children. J Pediatr 1976 Jun; 88(5): 874–9PubMedGoogle Scholar
  133. 133.
    Ginchansky E, Weinberger M. Relationship of theophylline clearance to oral dosage in children with chronic asthma. J Pediatr 1977 Nov; 91(4): 655–60PubMedGoogle Scholar
  134. 134.
    Ko JW, Jang IJ, Shin JG, et al. Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers. Clin Pharmacol Ther 1999 Jun; 65(6): 606–14PubMedGoogle Scholar
  135. 135.
    Tammara B, Trang JM, Miyamoto G, et al. The effects of concomitant administration of theophylline and toborinone on the pharmacokinetics of both compounds in poor and extensive metabolizers via CYP2D6. J Clin Pharmacol 2002 Jun; 42(5): 492–500PubMedGoogle Scholar
  136. 136.
    Dodson WE. Nonlinear kinetics of phenytoin in children. Neurology 1982 Jan; 32(1): 42–8PubMedGoogle Scholar
  137. 137.
    Valodia PN, Seymour MA, McFadyen ML, et al. Validation of population pharmacokinetic parameters of phenytoin using the parallel Michaelis-Menten and first-order elimination model. Ther Drug Monit 2000 Jun; 22(3): 313–9PubMedGoogle Scholar
  138. 138.
    Takahashi H, Ishikawa S, Nomoto S, et al. Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children. Clin Pharmacol Ther 2000 Nov; 68(5): 541–55PubMedGoogle Scholar
  139. 139.
    Pons G, d’Athis P, Rey E, et al. Gentamicin monitoring in neonates. Ther Drug Monit 1988; 10(4): 421–7PubMedGoogle Scholar
  140. 140.
    Bass KD, Larkin SE, Paap C, et al. Pharmacokinetics of once-daily gentamicin dosing in pediatric patients. J Pediatr Surg 1998 Jul; 33(7): 1104–7PubMedGoogle Scholar
  141. 141.
    Uijtendaal EV, Rademaker CM, Schobben AF, et al. Once-daily versus multiple-daily gentamicin in infants and children. Ther Drug Monit 2001 Oct; 23(5): 506–13PubMedGoogle Scholar
  142. 142.
    Lisby-Sutch SM, Nahata MC. Dosage guidelines for the use of vancomycin based on its pharmacokinetics in infants. Eur J Clin Pharmacol 1988; 35(6): 637–42PubMedGoogle Scholar
  143. 143.
    Gous AG, Dance MD, Lipman J, et al. Changes in vancomycin pharmacokinetics in critically ill infants. Anaesth Intensive Care 1995 Dec; 23(6): 678–82PubMedGoogle Scholar
  144. 144.
    Wrishko RE, Levine M, Khoo D, et al. Vancomycin pharmacokinetics and Bayesian estimation in pediatric patients. Ther Drug Monit 2000 Oct; 22(5): 522–31PubMedGoogle Scholar
  145. 145.
    Guay DR, Vance-Bryan K, Gilliland S, et al. Comparison of vancomycin pharmacokinetics in hospitalized elderly and young patients using a Bayesian forecaster. J Clin Pharmacol 1993 Oct; 33(10): 918–22PubMedGoogle Scholar
  146. 146.
    Birt JK, Chandler MH. Using clinical data to determine vancomycin dosing parameters. Ther Drug Monit 1990 Mar; 12(2): 206–9PubMedGoogle Scholar
  147. 147.
    Pleasants RA, Michalets EL, Williams DM, et al. Pharmacokinetics of vancomycin in adult cystic fibrosis patients. Antimicrob Agents Chemother 1996 Jan; 40(1): 186–90PubMedGoogle Scholar
  148. 148.
    Taber DJ, Fann AL, Malat G, et al. Evaluation of estimated and measured creatinine clearances for predicting the pharmacokinetics of vancomycin in adult liver transplant recipients. Ther Drug Monit 2003 Feb; 25(1): 67–72PubMedGoogle Scholar
  149. 149.
    Proctor NJ, Tucker GT, Rostami-Hodjegan A. Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Xenobiotica 2004 Feb; 34(2): 151–78PubMedGoogle Scholar
  150. 150.
    Wilkinson GR. Clearance approaches in pharmacology. Pharmacol Rev 1987; 39: 1–47PubMedGoogle Scholar
  151. 151.
    Hoog-Labouret N. Clinical trials in children: guidance ICH E11. In: Jacqz-Aigrain E, Choonara I, editors. Paediatric clinical pharmacology. New York: Taylor and Francis, 2006Google Scholar
  152. 152.
    Armitage P, Berry G. Statistical methods in medical research. 3rd ed. Oxford: Blackwell Science Ltd, 1994Google Scholar
  153. 153.
    Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981 Aug; 9(4): 503–12PubMedGoogle Scholar
  154. 154.
    Conroy S, Choonara I, Impicciatore P, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. BMJ 2000 Jan 8; 320(7227): 79–82PubMedGoogle Scholar
  155. 155.
    McIntyre J, Conroy S, Avery A, et al. Unlicensed and off label prescribing of drugs in general practice. Arch Dis Child 2000 Dec; 83(6): 498–501PubMedGoogle Scholar
  156. 156.
    Baber N, Pritchard D. Dose estimation for children. Br J Clin Pharmacol 2003 Nov; 56(5): 489–93PubMedGoogle Scholar
  157. 157.
    107th US Congress (1st session). Best pharmaceuticals for children act. Public Law 2002; 107–109Google Scholar
  158. 158.
    European Commission. Better medicines for children: proposed regulatory actions on paediatric medicinal products, 2002 [on-line]. Available from URL: http://pharmacos.eudra.org/F2/pharmacos/docs/Doc2002/feb/cd_pediatrics_en.pdf [Accessed 2006 Aug 8]
  159. 159.
    Kearns GL. The pediatric pharmacology research unit network: proof of concept. Paediatr Perinat Drug Ther 1999; 3: 9–14Google Scholar
  160. 160.
    Black DJ, Kunze KL, Wienkers LC, et al. Warfarin-fluconazole: II. a metabolically based drug interaction: in vivo studies. Drug Metab Dispos 1996 Apr; 24(4): 422–8PubMedGoogle Scholar
  161. 161.
    Takahashi H, Kashima T, Nomizo Y, et al. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin Pharmacol Ther 1998 May; 63(5): 519–28PubMedGoogle Scholar
  162. 162.
    Robertson Jr P, Hellriegel ET, Arora S, et al. Effect of modafinil at steady state on the single-dose pharmacokinetic profile of warfarin in healthy volunteers. J Clin Pharmacol 2002 Feb; 42(2): 205–14PubMedGoogle Scholar
  163. 163.
    Karachalios G, Charalabopoulos K. Biliary excretion of antimicrobial drugs. Chemotherapy 2002; 48(6): 280–97PubMedGoogle Scholar
  164. 164.
    Zamboni L. Electron microscopic studies of blood embryogenesis in humans: I. the ultrastructure of the fetal liver. J Ultrastruct Res 1965 Jun; 12(5): 509–24PubMedGoogle Scholar
  165. 165.
    Blanco JG, Harrison PL, Evans WE, et al. Human cytochrome P450 maximal activities in pediatric versus adult liver. Drug Metab Dispos 2000 Apr; 28(4): 379–82PubMedGoogle Scholar
  166. 166.
    Fawzy A, Alcorn J. Validating the assumptions of an ontogeny model of hepatic drug clearance mechanisms [abstract]. Drug Metab Rev 2004; 36 Suppl. 1: 340Google Scholar
  167. 167.
    Evans WE, Relling MV, de Graaf S, et al. Hepatic drug clearance in children: studies with indocyanine green as a model substrate. J Pharm Sci 1989 Jun; 78(6): 452–6PubMedGoogle Scholar
  168. 168.
    Price PS, Conolly RB, Chaisson CF, et al. Modeling inter-individual variation in physiological factors used in PBPK models of humans. Crit Rev Toxicol 2003; 33(5): 469–503PubMedGoogle Scholar
  169. 169.
    Pacifici GM, Taddeucci-Brunelli G, Rane A. Clonazepam serum protein binding during development. Clin Pharmacol Ther 1984 Mar; 35(3): 354–9PubMedGoogle Scholar
  170. 170.
    Schaad UB, Hayton WL, Stoeckel K. Single-dose ceftriaxone kinetics in the newborn. Clin Pharmacol Ther 1985 May; 37(5): 522–8PubMedGoogle Scholar
  171. 171.
    Benson JM, Boudinot FD, Pennell AT, et al. In vitro protein binding of cefonicid and cefuroxime in adult and neonatal sera. Antimicrob Agents Chemother 1993 Jun; 37(6): 1343–7PubMedGoogle Scholar
  172. 172.
    van Kalken C, Giaccone G, van der Valk P, et al. Multidrug resistance gene (P-glycoprotein) expression in the human fetus. Am J Pathol 1992 Nov; 141(5): 1063–72PubMedGoogle Scholar
  173. 173.
    Fakhoury M, Litalien C, Medard Y, et al. Localization and mRNA expression of CYP3A and P-glycoprotein in human duodenum as a function of age. Drug Metab Dispos 2005; 33(11): 1603–7PubMedGoogle Scholar
  174. 174.
    Bjorkmann S. Prediction of cytochrome P450-mediated hepatic drug clearance in neonates, infants and children: how accurate are available scaling methods. Clin Pharmacokinet 2006; 45(1): 1–11Google Scholar
  175. 175.
    Rane A. Phenotyping of drug metabolism in infants and children: potentials and problems. Pediatrics 1999 Sep; 104(3 Pt 2): 640–3PubMedGoogle Scholar
  176. 176.
    Leeder JS, Gotschall RR, Gaedigk A, et al. Acquisition of functional CYP2D6 and CYP3A4 activities in vivo in the first year of life [abstract]. Drug Metab Rev 2000; 32 Suppl. 2: 281Google Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  • Trevor N. Johnson
    • 1
  • Amin Rostami-Hodjegan
    • 1
    • 2
  • Geoffrey T. Tucker
    • 1
    • 2
  1. 1.Simcyp LimitedBlades Enterprise CentreSheffieldUK
  2. 2.Academic Unit of Clinical Pharmacology, Pharmacokinetics and Pharmacogenetics GroupUniversity of Sheffield, Royal Hallamshire HospitalSheffieldUK

Personalised recommendations